Department of respiratory disease
Montpellier, 34295, France
NCT Number: NCT03102749
New insights of small airway contribution to asthma have been gained. Poor levels of control and recurrent exacerbations were shown to have the phenotypic counterpart of asthma with predominant small airway involvement. Very few pathological specificities were identified at this site: mast cells infiltration was suggested as the specific inflammatory change when compared to the proximal airways.Biomarkers in asthma are still complex to validate, especially in the blood, since compartmentalisation is intense in the lung and the airways, a property attributed to the filtering role of the lung to maintain homeostasis. Over the last few years, Fraction exhaled Nitric Oxide (FENO) was developed as a non-invasive and indirect reflection of airway eosinophilic inflammation]. In the blood, peripheral eosinophil counts were shown as a correct T helper 2 (TH2)-phenotype identifier but not perfectly related to airway eosinophilic infiltration. Club cell secretory protein (SCGB1A1) levels have been shown to have some relevance in asthma, chronic obstructive pulmonary disease (COPD), BOS, sarcoidosis, and lung cancer.A biomarker for small airway disease in asthma may improve the management of the disease, identify areas of therapeutic resistance and constitute a therapeutic guidance tool. In this study, investigators aimed to assess small airway involvement in asthmatic women as far as they could. For this purpose, investigators analysed trends in air trapping by acquiring expiratory CT slices at each dose during a bronchoprovocation test with metacholine. Biomarkers were subsequently tested and confronted to clinical and demographical characteristics in their ability to predict the small airway involvement index obtained at CT.
Looking for future studies?
Notify Me18 year–85 year
Female
Observational
Montpellier, 34295, France
Patients will be recruited in the respiratory department of University Hospital in Montpellier (France) from June 2012 to March 2014. All patients are asthmatics, in order to avoid any gender-related biases, investigators decided to include only women. All participants had normal range spirometry, specifically regarding forced expiratory volume. Each patient will undergo a bronchial provocation test coupled with a thoracic CT scan. Bronchial and alveolar Nitric Oxyde will also be measured, a blood sample will be obtained in order to measure biomarker concentrations, and the patients will be asked to answer the validated Asthma Control Questionnaire in order to quantify asthma control.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Investigators perform a metacholine provocation test where expiratory CT slices were acquired at each dose
Time frame: 4 hours (after the enrollment)
Baseline versus post-methacholine challenge
Time frame: 4 hours (after the enrollment)
Baseline versus post-methacholine challenge
Time frame: Baseline
Analysis of CT imaging
Time frame: Baseline
Clara cell 10 kD protein levels in blood
Time frame: Baseline
Exhaled nitric oxide level
Time frame: Baseline
Alveolar nitric oxide level
University Hospital, Montpellier
Other
Acronym: SCANN'AIR
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05226416
Anemia, Arrhythmias, Cardiac
Moscow, Russia
View Trial DetailsNCT02575326
Asthma, Body Weight
Detroit, Michigan, United States
View Trial DetailsNCT00634036
Asthma, Body Weight
Pittsburgh, Pennsylvania, United States
View Trial DetailsNCT02490566
Asthma, Behavior
Miami, Florida, United States
View Trial Details